semaglutide

weight loss drugs obesity
Biotech

Skye's CB1 blocker fails to reduce weight in obesity study

Skye Bioscience’s obesity candidate has failed to reduce weight in a phase 2 study, marking another setback for the CB1 inhibitor class.
James Waldron Oct 6, 2025 7:55am
weight loss scale weigh measure tape obesity overweight

Pfizer’s new prize Metsera touts 14% weight loss for GLP-1

Sep 30, 2025 6:40am
weight loss scale weigh measure tape obesity overweight

Lilly rounds out orforglipron data ahead of obesity filings

Sep 17, 2025 9:00am
head to head against clash football helmets fight combat

BrightGene tops Novo drug in diabetes ahead of Zepbound showdown

Jun 23, 2025 2:30pm
Eli Lilly

Lilly's oral GLP-1 delivers Ozempic-like efficacy in phase 3

Apr 17, 2025 6:45am
obesity overweight weight loss weigh

Novo links CagriSema to 16% weight loss, sending stock down

Mar 10, 2025 9:30am